The Phase 3 TRIUMPH program is generating the data the FDA requires, and if the trials read out as expected, the retatrutide FDA approval story that began with a striking Phase 2 paper in 2023 will likely have its next chapter written in 2026
Commonly discussed issues include nausea, vomiting, diarrhea, abdominal pain, and constipation
Just color change and warmth
If you let your healthcare provider know that youre worried about the financial aspect of semaglutide GLP-1 treatment, they will discuss ways to manage the expense, such as choosing generic options, accessing savings cards, or using an HSA or FSA to pay for the medication
Heres where most practice-building advice gets dangerously misleading, so Im going to be blunt about the numbers